Repligen alleges BMS arthritis drug infringes patent
The patent covers methods of using CTLA4-Ig to treat rheumatoid arthritis, as well as other therapeutic methods. The FDA approved Bristol Myers Squibb’s (BMS’) application to market CTLA4-Ig,
The US Food and Drug Administration (FDA) is set to review Kowa Pharmaceuticals America’s new drug application (NDA) for K-911, an investigational once-daily eye drop aimed at reducing intraocular pressure (IOP) in open-angle glaucoma (OAG) or ocular hypertension (OHT) patients.